Patient Dosing Underway in Company's First Clinical Program
NOVATO, Calif., April 21 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. ("Bennu"), has initiated the Company's first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia(TM) program. Convivia(TM) is Bennu's proprietary, oral formulation of 4-MP designed to reduce peak systemic acetaldehyde levels in ALDH2 deficient persons following alcohol consumption.
ALDH2 deficiency, sometimes referred to as "Asian flushing syndrome," is an inherited metabolic disorder affecting 40% to 50% of East Asian populations, impairing the activity of the liver enzyme aldehyde dehydrogenase ("ALDH2"). When people with ALDH2 deficiency drink alcoholic beverages, there is an accumulation of acetaldehyde, a carcinogenic intermediate in the metabolism of ethanol, in blood and tissues. Published retrospective studies have observed a significant correlation between recurrent drinkers with ALDH2 deficiency and an increase in risk for digestive tract cancers, liver diseases, late-onset Alzheimer's disease and other serious health disorders. In addition to the long-term health risks, elevated acetaldehyde levels produce acute symptoms, including facial flushing, tachycardia (rapid heart rate), headache, nausea and dizziness.
Although ALDH2 deficient people suffer from unpleasant reactions and face long-term health risks, a substantial proportion of them are recurring drinkers of alcoholic beverages. Currently there are no approved treatments for ALDH2 deficiency, and people with this disorder could potentially benefit from a treatment that reduces acetaldehyde toxicities.
Convivia(TM) is designed to reduce peak systemic acetaldehyde levels in ALDH2 deficient persons following alcohol consumption. 4-MP, the active ingredient in Convivia(TM) and used in this Phase IIa study, is FDA-approved in an injectible formulation for other indications, but is investigational for treatment of acetaldehyde toxicities associated with ethanol exposure in ALDH2 deficient subjects.
Ted Daley, president of Bennu, stated, "ALDH2 deficiency is fueling a public health concern among clinical geneticists within the Asian medical community, which underscores the need to address this patient population with an effective treatment option. Although the risks of cancers and other health problems associated with this disorder have been documented in numerous studies over the past several years, they are not widely known to the general population or to the substantial proportion of Asians who are at risk. Even light to moderate ethanol intake may expose people with this condition to increased risks for serious diseases without them realizing it."
Phase IIa Clinical Trial of Oral 4MP
Bennu's Phase IIa clinical study is being conducted in Hawaii. The study is examining an oral administration of the current liquid injectible dose form of 4-MP that is marketed in the United States for other indications. Up to 32 subjects of Japanese descent who have a history of flushing reactions from alcohol will participate in a randomized, double-blind, placebo-controlled, dose escalation study of this orally administered liquid 4-MP or placebo, concomitant with ethanol. Participants will give subjective responses on severity of their symptomatic reactions and investigators will measure their blood levels of acetaldehyde and ethanol as well as heart rate and skin temperature, in order to evaluate tolerability, safety and efficacy of 4-MP at various dose levels. The results of the study are expected in June 2008.
About Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp.'s business consists of two segments: its 100% ownership of development stage biotechnology company Raptor Pharmaceutical Inc. ("Raptor Inc."); and its 100% ownership of clinical-stage development company Bennu Pharmaceuticals Inc. Raptor Inc. bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor- associated protein ("RAP") and related proteins, while Bennu advances clinical-stage product candidates towards marketing approval and commercialization.
Raptor Inc.'s preclinical programs target cancer, neurodegenerative disorders and infectious diseases. HepTide(TM) is designed to utilize engineered RAP-based peptides conjugated to drugs to target their delivery to the liver to potentially treat primary liver cancer and hepatitis. In neurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) are currently undergoing evaluation at Stanford University in cell culture and preclinical models for their ability to enhance the transport of molecules from blood to brain. In an effort to protect its novel approach, Raptor Inc. currently has five patent applications in review in the U.S., and countries in Europe and Asia, as well as two provisional patent applications licensed from Washington University. In addition, Raptor Inc. has recently submitted two new provisional patent applications in the U.S., the first of which covers a new family of RAP peptides, and the second application to further support and expand its coverage in specific disease indications.
Bennu executes the clinical development of product candidates developed internally at Raptor and in-licensed candidates that are: 1) new chemical entities in mid-to-late stage clinical development; 2) currently approved drugs with potential efficacy in additional indications; and 3) treatments that may be repurposed or reformulated as potentially more effective or convenient treatments for their currently approved indications. Bennu's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency and nephropathic cystinosis.
For additional information, please visit http://www.raptorpharma.com.
FORWARD LOOKING STATEMENTS
This document contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements relate to future events or our future results of operation or
future financial performance, including, but not limited to the following
statements: the Company's ability to successfully develop Convivia(TM) or
any of its other drug product candidates or technologies; the ability of
Convivia(TM) to reduce peak systemic acetaldehyde levels in ALDH2 deficient
persons following alcohol consumption; and the Company's ability to
continue and conclude the Phase IIa study of the liquid injectible dose
form of 4-MP. These statements are only predictions and involve known and
unknown risks, uncertainties and other factors, which may cause our actual
results to be materially different from these forward-looking statements.
Factors which may significantly change or prevent our forward looking
statements from fruition include that we may be unsuccessful in developing
any products or acquiring products; that our technology may not be
validated as we progress further and our methods may not be accepted by the
scientific community; that we are unable to retain or attract key employees
whose knowledge is essential to the development of our products; that
unforeseen scientific difficulties develop with our process; that our
patents are not sufficient to protect essential aspects of our technology;
that competitors may invent better technology; that our products may not
work as well as hoped or worse, that our products may harm recipients; and
that we may not be able to raise sufficient funds for development or
working capital when we require it. As well, our products may never develop
into useful products and even if they do, they may not be approved for sale
to the public. We caution readers not to place undue reliance on any such
forward-looking statements, which speak only as of the date they were made.
Certain of these risks, uncertainties, and other factors are described in
greater detail in our filings from time to time with the Securities and
Exchange Commission (the "SEC"), which we strongly urge you to read and
consider, including our Registration Statement on Form SB-2, as amended,
that was declared effective on July 10, 2006; our annual report on Form
10-KSB filed with the SEC on November 13, 2007; and our Form 10-QSB filed
with the SEC on April 14, 2008, all of which are available free of charge
on the SEC's web site at http://www.sec.gov. Subsequent written and oral
forward-looking statements attributable to us or to persons acting on our
behalf are expressly qualified in their entirety by the cautionary
statements set forth in our reports filed with the SEC. We expressly
disclaim any intent or obligation to update any forward-looking statements.
For more information, please contact:
The Ruth Group
Sara Ephraim (investors) Janine McCargo (media)
(646) 536-7002 (646) 536-7033
|SOURCE Raptor Pharmaceuticals Corp.|
Copyright©2008 PR Newswire.
All rights reserved